Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03683719
Recruitment Status : Completed
First Posted : September 25, 2018
Results First Posted : April 19, 2021
Last Update Posted : May 13, 2021
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Tracking Information
First Submitted Date  ICMJE September 21, 2018
First Posted Date  ICMJE September 25, 2018
Results First Submitted Date  ICMJE March 23, 2021
Results First Posted Date  ICMJE April 19, 2021
Last Update Posted Date May 13, 2021
Actual Study Start Date  ICMJE November 28, 2018
Actual Primary Completion Date March 6, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 15, 2021)
Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16. [ Time Frame: Week 0 to Week 16. ]
IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and delgocitinib cream vehicle.
Original Primary Outcome Measures  ICMJE
 (submitted: September 21, 2018)
Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement (IGA 0/1) from baseline to Week 16. [ Time Frame: Week 0 to Week 16. ]
IGA is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 22, 2021)
  • Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16. [ Time Frame: Week 0 to Week 16. ]
    HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The lowest HECSI score is 0 and the highest possible is 360. A higher HECSI score is indicating more severe hand eczema. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. A mixed model for repeated measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib cream doses and delgocitinib cream vehicle.
  • Time to IGA-CHE Treatment Success. [ Time Frame: Week 0 to Week 16. ]
    Time to IGA-CHE treatment success response is defined as the time from baseline to first assessment of an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 21, 2018)
  • Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16. [ Time Frame: Week 0 to Week 16. ]
    HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area).
  • Time to IGA 0/1. [ Time Frame: Week 0 to Week 16. ]
    Time to IGA 0/1 response is defined as the time from baseline to first assessment of an IGA 0/1.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Official Title  ICMJE A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema
Brief Summary The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Chronic Hand Eczema
Intervention  ICMJE
  • Drug: Delgocitinib cream
    Cream for topical application.
    Other Name: LEO 124249 cream
  • Drug: Delgocitinib cream vehicle
    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
    Other Name: LEO 124249 cream vehicle
Study Arms  ICMJE
  • Experimental: Delgocitinib cream 1 mg/g
    Delgocitinib cream applied twice daily for 16 weeks.
    Intervention: Drug: Delgocitinib cream
  • Experimental: Delgocitinib cream 3 mg/g
    Delgocitinib cream applied twice daily for 16 weeks.
    Intervention: Drug: Delgocitinib cream
  • Experimental: Delgocitinib cream 8 mg/g
    Delgocitinib cream applied twice daily for 16 weeks.
    Intervention: Drug: Delgocitinib cream
  • Experimental: Delgocitinib cream 20 mg/g
    Delgocitinib cream applied twice daily for 16 weeks.
    Intervention: Drug: Delgocitinib cream
  • Placebo Comparator: Delgocitinib cream vehicle
    Delgocitinib cream vehicle applied twice daily for 16 weeks.
    Intervention: Drug: Delgocitinib cream vehicle
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 8, 2020)
258
Original Estimated Enrollment  ICMJE
 (submitted: September 21, 2018)
250
Actual Study Completion Date  ICMJE April 20, 2020
Actual Primary Completion Date March 6, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Age 18 years or above.
  • Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for more than 3 months or returned twice or more within the last 12 months.
  • Disease severity graded as mild to severe according to IGA (i.e., IGA ≥2).
  • Recent history (within 1 year before the screening visit) of inadequate response to topical corticosteroid treatment or topical corticosteroid treatment being medically inadvisable.
  • Diagnostic patch testing performed within 3 years prior to the screening visit.

Key Exclusion Criteria:

  • Concurrent skin diseases on the hands e.g tinnea manuum.
  • Active atopic dermatitis in regions other than the hands or psoriasis requiring medical treatment.
  • Clinically significant infection (e.g., impetiginised hand eczema) on the hands.
  • Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 4 weeks prior to baseline.
  • Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks prior to baseline.
  • Receipt of live attenuated vaccines 4 weeks prior to baseline.
  • Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4 (PDE-4) inhibitors, pimecrolimus, tacrolimus) or topical corticosteroids on the hands within 2 weeks prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to baseline.
  • Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e., subjects must not start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline.
  • Other cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 1 week prior to baseline.
  • Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 1 week prior to baseline.
  • Receipt of any marketed or investigational biologic agents within 6 months or 5 half-lives prior to baseline or until cells count returns to normal, whichever is longer.
  • Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline.
  • Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with a positive blood test for tuberculosis at screening.
  • History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications.
  • Any disorder which is not stable and in the investigator's opinion could affect the safety of the subject, influence the findings of the trial, or impede the subject's ability to complete the trial.
  • Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Denmark,   Germany,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03683719
Other Study ID Numbers  ICMJE LP0133-1273
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Clinical Study Report (CSR)
URL: https://www.leopharmatrials.com/For-professionals
Responsible Party LEO Pharma
Study Sponsor  ICMJE LEO Pharma
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Expert LEO Pharma
PRS Account LEO Pharma
Verification Date April 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP